Drug intelligence / Profile preview

NVP-1805-R2

Development stage: Unknown
Lead developer: Navipharm
Modality: Small Molecules
Administration: Oral

Overview

**NVP-1805-R2** is an oral fixed-dose combination of **rosuvastatin** and **ezetimibe** developed by NVP Healthcare for lipid lowering in dyslipidemia. Rosuvastatin competitively inhibits 3-hydroxy-3-methylglutaryl-coenzyme A reductase, reducing hepatic cholesterol synthesis, while ezetimibe inhibits Niemann-Pick C1-like protein 1-mediated intestinal cholesterol absorption. In a Phase 1 healthy-volunteer pharmacokinetic study registered as NCT03802526, the rosuvastatin/ezetimibe fixed-dose combination was evaluated alone and with telmisartan. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/33326064/))

Other names: rosuvastatin + ezetimiberosuvastatin/ezetimibe

Targets

AGTR1 (Angiotensin II Type-1 receptor)NPC1L1 (Niemann-pick C1-Like 1 transporter)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)

Beyond the preview

Go deeper on NVP-1805-R2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVP-1805-R2.

Explore the full profile